This inventor holds 1 USPTO granted patent and 1 published patent application and 1 EPO patent. Top assignees: Centre National De La Recherche Scientifique, National Institute of Health and Medical Research, Pep-Therapy. Active years: 2021.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:


Years Active: 2021
Title: Sophie Lebel Binay: Innovator in Cell Penetrating Peptides
Introduction
Sophie Lebel Binay is a notable inventor based in Villejuif, France. She has made significant contributions to the field of biotechnology, particularly in the development of cell penetrating peptides. Her innovative work focuses on enhancing the delivery of cargo molecules into cells, which has important implications for medical research and treatment.
Latest Patents
Sophie holds a patent for "Cell penetrating peptides with improved internalization properties." This patent describes a method for delivering a cargo molecule into a cell by linking it to a cell penetrating peptide. Additionally, her work includes chimeric constructs that comprise cell penetrating moieties, showcasing her innovative approach to cellular delivery systems.
Career Highlights
Throughout her career, Sophie has worked with prestigious institutions such as Sorbonne Université and the Institut National de la Santé et de la Recherche Médicale. Her experience in these organizations has allowed her to collaborate with leading experts in the field and contribute to groundbreaking research.
Collaborations
Sophie has collaborated with notable colleagues, including Angelita Rebollo and Jesus Maria Fominaya Gutierrez. These partnerships have enriched her research and expanded the impact of her innovations in biotechnology.
Conclusion
Sophie Lebel Binay is a pioneering inventor whose work in cell penetrating peptides is paving the way for advancements in medical science. Her contributions are vital for improving the efficacy of drug delivery systems, ultimately benefiting patient care and treatment outcomes.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile